Effective management of severe cutaneous mastocytosis in young children with omalizumab (Xolair® )

• DOI: 10.1111/ced.13408
• Publication Date: 2018-02-16T11:23:19Z
• Authors: J. D. M. Hughes; T. Olynyc; H. Chapdelaine; L. Segal; B. Miedzybrodzki; M. Ben-Shoshan
• Keywords: Omalizumab; Cutaneous Mastocytosis

Omalizumab (Xolair®) is an anti‐IgE monoclonal antibody, which may benefit adults with systemic mastocytosis. We report effective treatment omalizumab in two toddlers severe diffuse cutaneous Our cases offer preliminary evidence to support the safe use of paediatric patients